UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington D. C. 20549


                                    FORM 8-K

              CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                      SECURITIES AND EXCHANGE ACT OF 1934.


                                  June 30, 2005
                Date of Report (Date of Earliest Event Reported)



                             DNAPrint genomics, Inc.
               (Exact name of Registrant as specified in charter)



                         Commission File Number: 0-31905

              Utah                                      59-2780520
     (State of Incorporation)                    (I.R.S. Employer I.D. No)


                     900 Cocoanut Avenue, Sarasota, FL 34236
                    (Address of Principal Executive Offices)


                                 (941) 366-3400
              (Registrant's Telephone Number, Including Area Code)


      Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[_]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[_]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

[_]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

[_]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))
<PAGE>

Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

      On June 30, 2005, the Registrant issued to Dutchess Private Equities Fund,
II, L.P. ("Dutchess") a promissory note (the "Note") in the amount of $1,560,000
for a purchase price of $1,300,000.

      As previously reported, on September 28, 2004, the Registrant entered into
an Investment Agreement (the "Investment Agreement") with Dutchess, pursuant to
which Dutchess has committed to purchase common stock of the Registrant up to an
aggregate purchase price of $35 million over a two year period. The Dutchess
Agreement provides that the Registrant from time to time may deliver a put
notice to Dutchess, and Dutchess is obliged to purchase the dollar amount of
common stock set forth in the notice.

      The Note is due and payable in full on January 3, 2006. Other than the
discount inherent in its purchase price, the Note is noninterest-bearing. The
note will be repaid using 50% of the proceeds of each put notice delivered by
the Registrant to Dutchess under the Investment Agreement. The required
repayments under the Note increase if the Registrant raises additional capital
during the term of the Note (other than capital raised under facilities in
existence as of the date of the Note).

      In connection with the note, the Registrant also paid Dutchess a facility
fee of $65,000 and issued to Dutchess 25 million shares of restricted common
stock, which are required to be registered for resale by Dutchess in the next
registration statement filed by the Registrant.


Item 2.03 CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN
          OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT.

          See Item 1.01 above.

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                                DNAPrint genomics, Inc.


                                                By: /s/ Richard Gabriel
                                                    --------------------------
                                                    Richard Gabriel, President
{"company-data": {"conformed-name": "DNAPRINT GENOMICS INC", "cik": "0001127354", "assigned-sic": "8731", "irs-number": "592780520", "state-of-incorporation": "UT", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-31905", "film-number": "05943683"}, "business-address": {"street1": "900 COCONUT AVE.", "city": "SARASOTA", "state": "FL", "zip": "34231", "phone": "9413663400"}, "mail-address": {"street1": "900 COCOANUT AVENUE", "street2": "NO SUITE", "city": "SARASOTA", "state": "FL", "zip": "34231"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington D. C. 20549

                                    FORM 8-K

              CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                      SECURITIES AND EXCHANGE ACT OF 1934.

                                  June 30, 2005
                Date of Report (Date of Earliest Event Reported)

                             DNAPrint genomics, Inc.
               (Exact name of Registrant as specified in charter)

                         Commission File Number: 0-31905

              Utah                                      59-2780520
     (State of Incorporation)                    (I.R.S. Employer I.D. No)

                     900 Cocoanut Avenue, Sarasota, FL 34236
                    (Address of Principal Executive Offices)

                                 (941) 366-3400
              (Registrant's Telephone Number, Including Area Code)

      Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[_]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[_]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

[_]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

[_]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

      On June 30, 2005, the Registrant issued to Dutchess Private Equities Fund,
II, L.P. ("Dutchess") a promissory note (the "Note") in the amount of $1,560,000
for a purchase price of $1,300,000.

      As previously reported, on September 28, 2004, the Registrant entered into
an Investment Agreement (the "Investment Agreement") with Dutchess, pursuant to
which Dutchess has committed to purchase common stock of the Registrant up to an
aggregate purchase price of $35 million over a two year period. The Dutchess
Agreement provides that the Registrant from time to time may deliver a put
notice to Dutchess, and Dutchess is obliged to purchase the dollar amount of
common stock set forth in the notice.

      The Note is due and payable in full on January 3, 2006. Other than the
discount inherent in its purchase price, the Note is noninterest-bearing. The
note will be repaid using 50% of the proceeds of each put notice delivered by
the Registrant to Dutchess under the Investment Agreement. The required
repayments under the Note increase if the Registrant raises additional capital
during the term of the Note (other than capital raised under facilities in
existence as of the date of the Note).

      In connection with the note, the Registrant also paid Dutchess a facility
fee of $65,000 and issued to Dutchess 25 million shares of restricted common
stock, which are required to be registered for resale by Dutchess in the next
registration statement filed by the Registrant.

Item 2.03 CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN
          OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT.

          See Item 1.01 above.

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                                DNAPrint genomics, Inc.

                                                By: /s/ Richard Gabriel
                                                    --------------------------
                                                    Richard Gabriel, President